Xspray Pharma
Xspray’s Dasynoc Faces FDA Approval Delay Due to Contract Manufacturing Issues
Dasynoc; Xspray Pharma; FDA; Complete Response Letter; manufacturing issues; good manufacturing practice; contract manufacturer; chronic myeloid leukemia; acute lymphoblastic leukemia; drug approval process